Efficacy of low-dose alteplase for treatment of hemodialysis catheter occlusions

Journal of Vascular Access

Volumn 6, Issue 2, 2005, Pages 76-82

  Haymond, J ^a   Shalansky, Karen ^b   Jastrzebski, J ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alteplase; Central venous catheters; Hemodialysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CATHFLO; CLOPIDOGREL; HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL OCCLUSION; CENTRAL VENOUS CATHETERIZATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEMODIALYSIS; HUMAN; LOW DRUG DOSE; MALE; PROSPECTIVE STUDY; RADIOTHERAPY; TREATMENT OUTCOME; VASCULAR PATENCY; VASCULAR SURGERY;

EID: 22944478640     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980500600206     Document Type: Article

References (17)

1. Besarab A, Brouwer D. Improving arteriovenous fistula construction: fistula first initiative. Hemodialysis Int 2004; 8: 199-206.
2. Stephens L, Haire W, Kotulak G. Are clinical signs accurate indicators of the cause of central venous catheter occlusion? JPEN 1995; 19: 75-9.
3. Besarab A, Raja RM. Vascular access for hemodialysis. In: Daugirdas JT, Blake PG, Ing RS, eds. Handbook of dialysis, 3rd edition. Philadelphia: Lippincott Williams & Wilkins 2001; 67-101.
4. Eyrich H, Walton T, Macon E, Howe A. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis. Am J Health-Syst Pharm 2002; 59: 1437-40.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for vascular access 2000. Am J Kidney Dis 2001; 37 (suppl 1): S139-81.
6. Davis S, Vermeulen L, Banton J, Schwartz B, Williams E. Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices, Am J Health-Sys Pharm 2000; 57: 1039-45.
7. Beathard G. Catheter thrombosis. Semin Dial 2001; 14: 144-5.
8. Timoney J, Malkin M, Leone D, et al. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices. J Clin.Oncol 2002; 20: 1918-22.
9. Paulsen D, Reisoether A, Aasen M, Fauchald P. Use of tissue plasminogen activator for reopening of clotted dialysis catheters. Nephron 1993; 64: 468-70.
10. Spry L, Miller G. Low-dose tPA for hemodialysis catheter clearance. Dial Transplant 2001; 30: 10-3.
11. Ponec D, Irwin D, Haire W, et al. Recombinant tissue plasminogen activator (Alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial - the cardiovascular thrombolytic to open occluded lines (COOL) efficacy trial. J Vasc Interv Radiol 2001; 12: 951-5.
12. Clase C, Crowther M, Ingram A, Cina C. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review. J Thromb Thrombolysis 2001; 11: 127-36.
13. Fink J, Capozzi D, Shermock K, et al. Alteplase for central catheter clearance: 1 mg/mL versus 2 mg/2 mL. Ann Pharmacother 2004; 38: 351-2.
14. Calis K, Cullinane A, Horne M. Bioactivity of cryopreserved alteplase solutions. Am J Health-Syst Pharm 1999; 56: 2056-57.
15. MacRae JM, Loh G, Djurdjeb O, et al. Short and long alteplase dwells in dysfunctional hemodialysis catheters. Hemodialysis Int 2005; 9: 189-95.
16. Nguyen T, Dikun M. Establishing an alteplase dosing protocol for hemodialysis-catheter thrombosis. Am J Health-Syst Pharm 2004; 61: 1922-4.
17. Little M, Walshe J. A longitudinal study of the repeated use of alteplase as therapy for tunnelled hemodialysis catheter dysfunction. Am J Kidney Dis 2002; 39: 1-15.